

Supporting Information

Pd-Catalyzed Desulfitative Arylation for Synthesis of 2,5-Diarylated Oxazole-4-Carboxylates with Dioxygen as the Terminal Oxidant

Xiaodong Tang^{†a}, Kai Yang^{†c}, Liying Zeng^b, Qiang Liu^{*b} and Huoji Chen^{*b}

^aGuangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, 1023 South Shatai Road, Baiyun District, Guangzhou 510515, P. R. China.

^bSchool of Traditional Chinese Medicine, Southern Medical University, 1023 South Shatai Road, Baiyun District, Guangzhou 510515, P. R. China. E-mail: gzlq2002@163.com; chenhuoji2005@126.com

^cSchool of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, Jiangxi 341000.


Table of Contents

General Information.....	[2]
Experimental Procedure for Compounds 3	[2]
Characterization Data for All Products 3	[2]
References.....	[8]
NMR Spectra for All Compounds 3	[9]

General Information


¹H and ¹³C NMR spectra were recorded on BRUKER DRX-400 spectrometer. The chemical shifts are referenced to signals at 7.26 and 77.0 ppm, respectively, and CDCl₃ is solvent with TMS as the internal standard. IR spectra were obtained either as potassium bromide pellets or as liquid films between two potassium bromide pellets with a spectrometer. GC-MS was obtained using electron ionization. HRMS was obtained with a LCMS-IT-TOF mass spectrometer. TLC was performed by using commercially prepared 100-400 mesh silica gel plates, and visualization was effected at 254 nm.

Experimental Procedure for Compounds 3




The mixture of 2-aryloxazole-4-carboxylate **1** (0.3 mmol), sodium arylsulfonates **2** (0.6 mmol), Pd(OAc)₂ (5 mol%), DPEphos (10 mol %), K₂CO₃ (0.6 mmol) in dioxane (3 mL) was stirred at 100 °C under O₂ for 20 h. At ambient temperature, the reaction mixture was diluted with H₂O (15 mL) and extracted with EtOAc (3 × 15 mL). The organic extracts were dried over MgSO₄. After filtration and evaporation of the solvents under reduced pressure, the crude product was purified by column chromatography on silica gel to afford desired product.

Characterization Data for All Products 3




Ethyl 2,5-diphenyloxazole-4-carboxylate (**3a**)¹

Yellow solid (71.2 mg, 81%); m.p. = 95-96 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.11 – 8.08 (m, 1H), 8.06 – 8.03 (m, 2H), 7.46 – 7.39 (m, 6H), 4.39 (q, *J* = 7.1 Hz, 2H), 1.36 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): ¹³C NMR (101 MHz, CDCl₃) δ 162.3, 159.8, 155.0, 131.0, 130.2, 128.8, 128.5, 128.3, 128.3, 127.1, 126.8, 126.4, 61.4, 14.2. MS (EI, 70 eV) *m/z*: 77, 105, 221, 293. IR (KBr): 3062, 2982, 1720, 1488, 1215, 1098, 710, 688 cm⁻¹.




Ethyl 5-(4-ethylphenyl)-2-phenyloxazole-4-carboxylate (3b)


Yellow oil (73.2 mg, 76%). ¹H NMR (400 MHz, CDCl₃) δ 8.18 – 8.14 (m, 2H), 8.04 (d, *J* = 8.2 Hz, 2H), 7.51 – 7.47 (m, 3H), 7.34 (d, *J* = 8.2 Hz, 3H), 4.47 (q, *J* = 7.1 Hz, 2H), 2.73 (q, *J* = 7.6 Hz, 2H), 1.44 (t, *J* = 7.1 Hz, 3H), 1.29 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.3, 159.5, 155.4, 146.9, 130.9, 128.7, 128.6, 127.9, 127.8, 126.8, 126.5, 124.5, 61.4, 28.8, 15.3, 14.3. IR (KBr): 2969, 1721, 1505, 1453, 1216, 1097, 711 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₂₀H₁₉NNaO₃ [M+Na]⁺, 344.1257; found, 344.1259.

**Ethyl 5-(4-(tert-butyl)phenyl)-2-phenyloxazole-4-carboxylate (3c)**


Yellow oil (76.4 mg, 73%). ¹H NMR (400 MHz, CDCl₃) δ 8.17 (s, 2H), 8.07 (d, *J* = 8.5 Hz, 2H), 7.57 – 7.48 (m, 5H), 4.48 (q, *J* = 7.1 Hz, 2H), 1.45 (t, *J* = 7.1 Hz, 3H), 1.38 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 162.4, 155.4, 153.7, 130.9, 128.7, 128.3, 127.8, 126.8, 126.5, 125.3, 124.3, 61.4, 34.9, 31.1, 14.3. IR (KBr): 2961, 1721, 1613, 1503, 1454, 1216, 1092, 710 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₂₂H₂₃NNaO₃ [M+Na]⁺, 372.1570; found, 372.1576.

**Ethyl 5-(4-fluorophenyl)-2-phenyloxazole-4-carboxylate (3d)²**

White solid (61.6 mg, 66%). m.p. = 112-113 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.17 – 8.10 (m, 4H), 7.50 – 7.45 (m, 3H), 7.17 (t, *J* = 8.7 Hz, 2H), 4.45 (q, *J* = 7.1 Hz, 2H), 1.42 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 163.7 (d, *J* = 250 Hz), 162.2, 159.6, 154.2, 131.0, 130.7 (d, *J* = 9 Hz), 128.8, 128.0, 126.8, 126.2, 123.3 (d, *J* = 3 Hz), 115.5 (d, *J* = 22 Hz), 61.5, 14.2. IR (KBr): 2984, 1712, 1603, 1503, 1455, 1090, 842, 705 cm⁻¹. MS (EI, 70 eV) *m/z*: 77, 95, 105, 239, 311.


**Ethyl 5-(4-chlorophenyl)-2-phenyloxazole-4-carboxylate (3e)²**

White solid (62.8 mg, 64%). m.p. = 117-118 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.15 – 8.11 (m, 2H), 8.10 – 8.07 (m, 2H), 7.49 – 7.44 (m, 5H), 4.45 (q, *J* = 7.1 Hz, 2H), 1.42 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.2, 159.8, 153.9, 136.3, 131.1, 129.7, 128.8, 128.7, 128.6, 126.8, 126.2, 125.5, 61.5, 14.2. IR (KBr): 2985, 1718, 1487, 1214, 1094, 755, 712 cm⁻¹. MS (EI, 70 eV) *m/z*: 77, 105, 139, 255, 327 (Cl³⁵).




Ethyl 5-(4-methoxyphenyl)-2-phenyloxazole-4-carboxylate (3f)³


White solid (55.2 mg, 57%); m.p. = 101-102 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.17 – 8.10 (m, 4H), 7.51 – 7.47 (m, 3H), 7.02 (d, *J* = 8.9 Hz, 2H), 4.47 (q, *J* = 7.1 Hz, 2H), 3.89 (s, 3H), 1.44 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.5, 161.1, 159.1, 155.4, 130.8, 130.2, 128.7, 127.0, 126.7, 126.5, 119.6, 113.8, 61.3, 55.4, 14.3. IR (KBr): 2926, 1715, 1505, 1212, 1091, 709 cm⁻¹. MS (EI, 70 eV) *m/z*: 77, 105, 135, 207, 251, 323.

**Ethyl 5-(2-bromophenyl)-2-phenyloxazole-4-carboxylate (3g)**


Yellow solid (82.4 mg, 74%); m.p. = 132-133 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.18 – 8.13 (m, 2H), 7.73 (dd, *J* = 8.0, 1.0 Hz, 1H), 7.58 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.51 – 7.42 (m, 4H), 7.41 – 7.36 (m, 1H), 4.33 (q, *J* = 7.1 Hz, 2H), 1.25 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.4, 161.0, 153.7, 133.0, 132.5, 131.6, 131.1, 130.7, 129.2, 128.8, 126.9, 126.9, 126.4, 123.8, 61.2, 14.0. IR (KBr): 2983, 1721, 1491, 1463, 1218, 1026, 767, 731, 692 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₁₈H₁₄BrNNaO₃ (Br⁷⁹) [M+Na]⁺, 394.0049; found, 394.0053.

**Ethyl 5-(3-bromophenyl)-2-phenyloxazole-4-carboxylate (3h)**

Yellow solid (83.5 mg, 75%); m.p. = 124-125 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.26 (s, 1H), 8.17 – 8.12 (m, 2H), 8.07 (d, *J* = 7.9 Hz, 1H), 7.57 (d, *J* = 8.0 Hz, 1H), 7.49 (s, 3H), 7.35 (t, *J* = 8.0 Hz, 1H), 4.45 (q, *J* = 7.1 Hz, 2H), 1.43 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.9, 160.1, 153.0, 133.0, 131.2, 131.1, 129.8, 129.0, 128.9, 128.8, 127.0, 126.9, 126.0, 122.3, 61.6, 14.2. IR (KBr): 2986, 1720, 1563, 1478, 1221, 1109, 746 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₁₈H₁₄BrNNaO₃ (Br⁷⁹) [M+Na]⁺, 394.0049; found, 394.0054.


**Ethyl 2-phenyl-5-(m-tolyl)oxazole-4-carboxylate (3i)**

Yellow oil (71.8 mg, 78%). ¹H NMR (400 MHz, CDCl₃) δ 8.18 – 8.13 (m, 2H), 7.91 (d, *J* = 7.3 Hz, 2H), 7.52 – 7.48 (m, 3H), 7.39 (t, *J* = 7.9 Hz, 1H), 7.29 (d, *J* = 7.5 Hz, 1H), 4.46 (q, *J* = 7.1 Hz, 2H), 2.45 (s, 3H), 1.43 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.2, 159.7, 155.2, 138.0, 131.0, 130.9, 129.0, 128.7, 128.2, 128.2, 127.0, 126.8, 126.4, 125.8, 61.3, 21.4, 14.2. IR (KBr): 2982, 1721, 1564, 1485, 1213, 1100, 712 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₁₉H₁₇NNaO₃ [M+Na]⁺, 330.1011; found, 330.1012.




Ethyl 5-(naphthalen-2-yl)-2-phenyloxazole-4-carboxylate (3j)

White solid (68.9 mg, 67%); m.p. = 116-117 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.68 (s, 1H), 8.22 – 8.19 (m, 2H), 8.17 – 8.13 (m, 1H), 7.98 – 7.92 (m, 2H), 7.89 – 7.85 (m, 1H), 7.58 – 7.49 (m, 5H), 4.49 (q, *J* = 7.1 Hz, 2H), 1.45 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.3, 159.8, 155.0, 133.8, 132.7, 131.0, 128.8, 128.8, 128.7, 128.5, 127.9, 127.6, 127.4, 126.8, 126.6, 126.3, 125.0, 124.3, 61.4, 14.3. IR (KBr): 2984, 1718, 1553, 1490, 1265, 1222, 1097, 754 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₂₂H₁₇NNaO₃ [M+Na]⁺, 366.1101; found, 366.1094.




Ethyl 2-phenyl-5-(thiophen-2-yl)oxazole-4-carboxylate (3k)⁴

Brown oli (56.5 mg, 63%). ¹H NMR (400 MHz, CDCl₃) δ 8.15 – 8.13 (m, 3H), 7.54 (dd, *J* = 5.0, 0.8 Hz, 1H), 7.50 – 7.47 (m, 3H), 7.17 (dd, *J* = 4.9, 4.0 Hz, 1H), 4.51 (q, *J* = 7.1 Hz, 2H), 1.48 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.1, 158.8, 150.9, 131.0, 130.1, 129.5, 128.7, 128.5, 127.6, 126.8, 126.2, 126.1, 61.4, 14.3. IR (KBr): 2927, 1663, 1605, 1576, 1511 cm⁻¹. MS (EI, 70 eV) *m/z*: 77, 105, 111, 227, 299.




Ethyl 5-phenyl-2-(p-tolyl)oxazole-4-carboxylate (3l)

White solid (69.1 mg, 75%); m.p. = 82-83 °C ¹H NMR (400 MHz, CDCl₃) δ 8.11 – 8.08 (m, 2H), 8.03 (d, *J* = 8.2 Hz, 2H), 7.50 – 7.42 (m, 3H), 7.27 (d, *J* = 8.0 Hz, 2H), 4.44 (q, *J* = 7.1 Hz, 2H), 2.39 (s, 3H), 1.41 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.3, 160.0, 154.7, 141.4, 130.1, 129.4, 128.4, 128.3, 128.1, 127.2, 126.8, 123.6, 61.3, 21.5, 14.2. IR (KBr): 2982, 1719, 1588, 1497, 1213, 1098, 1025, 761, 693 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₁₉H₁₇NNaO₃ [M+Na]⁺, 330.1101; found, 330.1102.




Ethyl 2-(4-methoxyphenyl)-5-phenyloxazole-4-carboxylate (3m)⁵

Yellow oil (67.8 mg, 70%). ¹H NMR (400 MHz, CDCl₃) δ 8.11 – 8.06 (m, 4H), 7.51 – 7.42 (m, 3H), 6.98 (d, *J* = 8.8 Hz, 2H), 4.45 (q, *J* = 7.1 Hz, 2H), 3.85 (s, 3H), 1.41 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.3, 161.8, 133.4, 130.0, 128.5, 128.4, 128.3, 128.3, 128.0, 127.2, 119.0, 114.1, 61.3, 55.3, 14.2. IR (KBr): 2984, 1718, 1614, 1503, 1218, 838, 741 cm⁻¹. MS (EI, 70 eV) *m/z*: 77, 105, 135, 207, 323.




Ethyl 2-(4-fluorophenyl)-5-phenyloxazole-4-carboxylate (3n)

White solid (78.4 mg, 84%); m.p. = 96-97 °C ¹H NMR (400 MHz, CDCl₃) δ 8.17 – 8.14 (m, 2H), 8.12 – 8.06 (m, 2H), 7.54 – 7.43 (m, 3H), 7.23 – 7.12 (m, 2H), 4.45 (q, *J* = 7.1 Hz, 2H), 1.42 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.5 (d, *J* = 251 Hz), 162.2, 159.0, 155.1, 130.3, 129.1 (d, *J* = 9 Hz), 128.5, 128.4, 128.3, 127.0, 122.8 (d, *J* = 3 Hz), 116.1 (d, *J* = 22Hz), 61.5, 14.2. IR (KBr): 2985, 1713, 1501, 1451, 1227, 1092, 840, 706 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₁₈H₁₄FNNaO₃ [M+Na]⁺, 334.0850; found, 334.0855.




Ethyl 2-(4-chlorophenyl)-5-phenyloxazole-4-carboxylate (3o)⁶

White solid (83.4 mg, 85%); m.p. = 96-97 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.10 – 8.02 (m, 4H), 7.50 – 7.40 (m, 5H), 4.43 (q, *J* = 7.1 Hz, 2H), 1.40 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.0, 158.7, 155.1, 137.1, 130.3, 129.0, 128.4, 128.3, 128.3, 128.0, 126.8, 124.7, 61.4, 14.1. IR (KBr): 2983, 1718, 1564, 1487, 1266, 1014, 1099, 755 cm⁻¹. MS (EI, 70 eV) *m/z*: 77, 105, 139, 206, 327 (Cl³⁵).



Ethyl 2-(4-bromophenyl)-5-phenyloxazole-4-carboxylate (3p)


White solid (87.9 mg, 79%); m.p. = 109-110 °C ¹H NMR (400 MHz, CDCl₃) δ 8.09 – 8.06 (m, 2H), 8.00 (d, *J* = 8.6 Hz, 2H), 7.61 (d, *J* = 8.6 Hz, 2H), 7.51 – 7.46 (m, 3H), 4.44 (q, *J* = 7.1 Hz, 2H), 1.41 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.0, 158.9, 155.2, 132.1, 130.4, 128.5, 128.3, 128.2, 126.9, 125.6, 125.2, 61.5, 14.2. IR (KBr): 2982, 2926, 1731, 1560, 1474, 1100, 758 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₁₈H₁₄BrNNaO₃ (Br⁷⁹) [M+Na]⁺, 394.0049; found, 394.0056.



Ethyl 5-phenyl-2-(4-(trifluoromethyl)phenyl)oxazole-4-carboxylate (3q)


White solid (94.2 mg, 87%); m.p. = 104-105 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, *J* = 8.2 Hz, 2H), 8.12 – 8.08 (m, 2H), 7.74 (d, *J* = 8.3 Hz, 2H), 7.53 – 7.47 (m, 3H), 4.46 (q, *J* = 7.1 Hz, 2H), 1.42 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.9, 158.3, 155.7, 132.5 (q, *J* = 33 Hz), 129.5, 128.6, 128.4, 127.0, 126.7, 125.8 (q, *J* = 4 Hz), 123.7 (q, *J* = 271 Hz), 61.5, 14.2. IR (KBr): 2963, 1721, 1619, 1495, 1128, 847, 756, 708 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₁₉H₁₄F₃NNaO₃ [M+Na]⁺, 384.0818; found,

384.0823.




Ethyl 2-(2-bromophenyl)-5-phenyloxazole-4-carboxylate (3r)

White solid (73.5 mg, 66%); m.p. = 96-97 °C ¹H NMR (400 MHz, CDCl₃) δ 8.21 – 8.16 (m, 2H), 8.07 – 8.05 (m, 1H), 7.72 – 7.70 (m, 1H), 7.53 – 7.39 (m, 4H), 7.34 – 7.30 (m, 1H), 4.45 (q, *J* = 7.1 Hz, 2H), 1.42 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.1, 158.4, 155.6, 134.3, 131.9, 131.8, 130.3, 128.5, 128.4, 127.9, 127.6, 127.3, 126.9, 121.2, 61.4, 14.2. IR (KBr): 2923, 1721, 1485, 1214, 1097, 822, 756, 694 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₁₈H₁₄BrNNaO₃ (Br⁷⁹) [M+Na]⁺, 394.0049; found, 394.0053.




Ethyl 2-(2-methoxyphenyl)-5-phenyloxazole-4-carboxylate (3s)²

Yellow oil (54.3 mg, 56%). ¹H NMR (400 MHz, CDCl₃) δ 8.16 – 8.13 (m, 2H), 8.05 – 8.03 (m, 1H), 7.52 – 7.36 (m, 4H), 7.06 – 7.01 (m, 2H), 4.44 (q, *J* = 7.1 Hz, 2H), 3.95 (s, 3H), 1.42 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.4, 158.5, 157.9, 154.7, 132.3, 130.7, 130.0, 128.4, 128.3, 127.9, 127.3, 120.5, 115.5, 111.8, 61.2, 55.9, 14.2. IR (KBr): 2961, 1718, 1488, 1215, 1103, 1023, 913, 745, 696 cm⁻¹. MS (EI, 70 eV) *m/z*: 77, 105, 135, 249, 323.



Ethyl 2-(3-methoxyphenyl)-5-phenyloxazole-4-carboxylate (3t)


Yellow oil (60.1 mg, 62%). ¹H NMR (400 MHz, CDCl₃) δ 8.11 – 8.08 (m, 2H), 7.75 – 7.71 (m, 1H), 7.68 – 7.67 (m, 1H), 7.53 – 7.46 (m, 3H), 7.39 (t, *J* = 8.0 Hz, 1H), 7.05 – 7.02 (m, 1H), 4.45 (q, *J* = 7.1 Hz, 2H), 3.89 (s, 3H), 1.42 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.2, 159.9, 159.7, 155.0, 130.3, 129.9, 128.5, 128.3, 128.2, 127.5, 127.1, 119.3, 117.6, 111.4, 61.4, 55.5, 14.2. IR (KBr): 2925, 1719, 1565, 1097, 1037, 758 cm⁻¹. HRMS (ESI) *m/z*: calcd for C₁₉H₁₇NNaO₄ [M+Na]⁺, 346.1050; found, 346.1046.



Ethyl 2-(naphthalen-1-yl)-5-phenyloxazole-4-carboxylate (3u)²


White solid (80.3 mg, 78%); m.p. = 121-122 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.26 (d, *J* = 8.6 Hz, 1H), 8.29 (d, *J* = 7.1 Hz, 1H), 8.22 – 8.16 (m, 2H), 7.99 (d, *J* = 8.2 Hz, 1H), 7.91 (d, *J* = 8.1 Hz, 1H), 7.69 (t, *J* = 7.3 Hz, 1H), 7.61 – 7.48 (m, 5H), 4.50 (q, *J* = 7.1 Hz, 2H), 1.46 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz,

CDCl₃) δ 162.4, 159.7, 154.7, 133.8, 131.8, 130.2, 130.2, 128.5, 128.4, 128.4, 128.2, 127.8, 127.1, 126.4, 125.9, 124.8, 122.9, 61.3, 14.2. IR (KBr): 2984, 1718, 1491, 1223, 1097, 757 cm⁻¹. MS (EI, 70 eV) m/z: 77, 105, 127, 155, 343.



Ethyl 5-phenyl-2-(thiophen-2-yl)oxazole-4-carboxylate (3v)

Yellow solid (66.4 mg, 74%); m.p. = 72-73 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.08 – 8.06 (m, 2H), 7.81 (s, 1H), 7.51 – 7.41 (m, 4H), 7.14 – 7.12 (m, 1H), 4.44 (q, *J* = 7.1 Hz, 2H), 1.40 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.0, 156.0, 154.5, 130.2, 129.3, 129.0, 128.6, 128.5, 128.3, 128.1, 127.9, 126.8, 61.4, 14.3. IR (KBr): 2983, 1721, 1594, 1494, 1207, 1094, 758 cm⁻¹. HRMS (ESI) m/z: calcd for C₁₆H₁₃NNaO₃ [M+Na]⁺, 322.0508; found, 322.0522.



Methyl 2,5-diphenyloxazole-4-carboxylate (3w)¹



White solid (66.1 mg, 79%); m.p. = 85-86 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.19 – 8.13 (m, 4H), 7.55 – 7.46 (m, 6H), 4.00 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 171.0, 162.60, 133.5, 131.0, 130.3, 130.0, 128.7, 128.4, 127.8, 126.9, 126.7, 126.2, 52.3. IR (KBr): 3061, 2952, 1721, 1489, 1102, 710, 688 cm⁻¹. MS (EI, 70 eV) m/z: 77, 105, 165, 279.



References

1. B. Liu, Y. Zhang, G. Huang, X. Zhang, P. Niu, J. Wu, W. Yu and J. Chang, *Org. Biomol. Chem.*, 2014, **12**, 3912.
2. J. Zheng, M. Zhang, L. Huang, X. Hu, W. Wu, H. Huang and H. Jiang, *Chem. Commun.*, 2014, **50**, 3609.
3. S. V. Kumar, B. Saraiah, N. C. Misra and H. Ila, *J. Org. Chem.*, 2012, **77**, 10752.
4. C. Verrier, T. Martin, C. Hoarau and F. Marsais, *J. Org. Chem.*, 2008, **73**, 7383.
5. L. Théveau, C. Verrier, P. Lassalas, T. Martin, G. Dupas, O. Querolle, L. V. Hijfte, F. Marsais and C. Hoarau, *Chem. Eur. J.*, 2011, **17**, 14450.
6. C. Verrier, C. Fiol-Petit, C. Hoarau and F. Marsais, *Org. Biomol. Chem.*, 2011, **9**, 6215.



NMR Spectra for All Compounds 3

3a





3b



3c





3d





3e





3f





3g





3h





3i





3j





3k





31





3m





3n





3o





3p





3q





3r





3s







3u



3v



3w

